Relay Therapeutics Income Statement (2019-2026) | RLAY

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.84M0.67M0.57M0.42M0.36M0.34M0.25M0.23M0.12M25.20M-0.00M10.01M7.68M0.68M7.00M3.00M
Operating items
Research & Development (Quarter)
45.15M44.97M51.91M51.67M60.51M66.90M67.28M82.83M88.20M81.49M77.50M82.40M91.99M76.62M68.08M73.81M63.90M68.26M55.41M70.56M
Selling, General & Administrative (Quarter)
14.42M14.68M15.55M16.07M17.46M16.07M16.37M19.58M20.12M18.48M16.77M19.80M20.14M19.75M16.90M18.74M13.63M12.13M12.21M11.03M
Other Operating Expenses (Quarter)
134.85M2.00M0.84M-4.59M0.20M3.26M-10.54M-1.00M-2.15M-1.20M-2.07M-1.83M-11.37M
Operating Expenses (Quarter)
194.42M61.66M68.29M63.14M78.18M86.24M73.10M101.40M106.17M98.78M92.19M100.37M100.76M96.37M84.98M92.55M77.52M80.39M67.63M81.59M
Operating Income (Quarter)
-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M
EBIT (Quarter)
-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M
Non-operating items
Interest & Investment Income (Quarter)
-0.08M0.07M-1.72M-8.13M-2.69M1.71M5.37M6.94M-0.28M2.69M3.19M8.95M8.55M8.27M32.04M7.81M7.11M6.41M25.55M-0.17M
Other Non Operating Income (Quarter)
0.18M0.16M0.27M0.68M1.02M1.72M5.35M6.94M7.54M7.84M8.70M8.98M8.54M8.26M8.97M7.80M6.47M6.24M5.74M5.30M
Non Operating Income (Quarter)
0.00M-0.02M0.02M0.01M-0.02M-0.00M-0.01M-0.00M0.00M0.03M-0.00M-0.01M0.00M-0.01M-0.63M-0.17M0.03M
Net income details
EBT (Quarter)
-193.74M-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-89.27M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M
Profit After Tax (Quarter)
-193.40M-60.83M-67.40M-62.05M-76.79M-84.17M-64.53M-94.24M-98.50M-63.04M-83.50M-81.39M-92.21M-84.26M-78.71M-76.04M-70.38M-73.49M-54.65M-73.46M
Income from Continuing Operations (Quarter)
-193.74M-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-89.27M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M
Consolidated Net Income (Quarter)
-193.74M-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-89.27M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M
Income towards Parent Company (Quarter)
-193.74M-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-89.27M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-193.74M-60.83M-67.46M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-89.27M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M
Additional items
EPS (Basic) (Quarter)
-2.11-0.66-0.71-0.74-0.85-0.77-0.67-0.83-0.92-0.61-0.73-0.63-0.70-0.63-3.39-0.46-0.43-0.43-0.20-0.44
EPS (Diluted) (Quarter)
-4.55-0.66-0.71-0.84-0.97-0.77-0.67-0.90-1.00-0.66-0.80-0.74-0.83-0.79-4.32-0.69-0.66-0.66-0.31-0.71
Shares Outstanding (Quarter)
91.94M92.69M95.14M108.29M108.64M110.91M112.23M121.32M121.68M122.23M122.58M130.84M132.82M140.23M142.87M169.23M171.26M172.39M171.59M179.85M
Shares Outstanding (Diluted) (Quarter)
42.62M92.69M95.14M95.14M95.14M110.91M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M
EBITDA (Quarter)
-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M
Interest Expenses (Quarter)
0.08M1.00M4.00M9.22M11.91M1.10M7.58M6.33M6.08M3.39M0.26M1.30M1.35M0.30M431.93M0.91M4.24M0.24M0.01M0.36M